Polycystic Ovary Syndrome (PCOS) renamed to Polyendocrine Ovarian Metabolic Syndrome (PMOS) for better diagnosis and treatment
The Endocrine Society, a global organization of scientists and physicians, has decided to rename Polycystic Ovary Syndrome (PCOS) to Polyendocrine Ovarian Metabolic Syndrome (PMOS). This change aims to improve diagnosis, treatment, and reduce stigma associated with the condition. The previous name, PCOS, was deemed inaccurate as it focused on ovarian cysts, leading to diagnostic delays and misperceptions. The new name better reflects the multi-pronged features of the condition, which include endocrine, metabolic, and ovarian dysfunction, encompassing issues like insulin resistance, hyperandrogenism, and neuroendocrine imbalances, beyond just ovarian cysts. A global implementation strategy is underway.
Key Points
- Polycystic Ovary Syndrome (PCOS) has been renamed to Polyendocrine Ovarian Metabolic Syndrome (PMOS).
- The renaming aims to improve diagnostic accuracy, facilitate treatment, and reduce stigma.
- The old name, PCOS, was considered inaccurate as ovarian cysts are not always present and the condition involves broader endocrine and metabolic dysfunctions.
- The new name better captures the multi-pronged features of the condition, including insulin, androgen, and neuroendocrine imbalances.
Exam Facts
- The Endocrine Society, a global organization, initiated the name change.
- The new name is Polyendocrine Ovarian Metabolic Syndrome (PMOS).
- PCOS affects an estimated 170 million women during their reproductive years globally.
- The article refers to a publication in The Lancet by Helena J. Teede et al.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.